Latest Breaking News On - Carsgen therapeutics holdings - Page 2 : comparemela.com

Carsgen's CT011 Achieves IND Clearance From The NMPA For The GPC3-Positive Stage Iiia Hepatocellular Carcinoma At High Risk Of Recurrence After Surgic...

CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting

CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia

/PRNewswire/ CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of.

CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival

/PRNewswire/ CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of.

Head-To-Head Survey: Moderna (NASDAQ:MRNA) and Codiak BioSciences (NASDAQ:CDAK)

Moderna (NASDAQ:MRNA – Get Free Report) and Codiak BioSciences (NASDAQ:CDAK – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings. Profitability This table compares Moderna and Codiak BioSciences’ net […]